Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID
Medicines For Europe And IGBA Set Out Policy Priorities At Athens Conference
Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.
You may also be interested in...
Sandoz’s Rebecca Guntern has been named as interim president of Medicines for Europe for a three-month term, after Teva’s Christoph Stoller stepped down at the end of his two-year tenure.
Medicines for Europe has made a series of recommendations to improve the contribution of generics, biosimilars and value-added medicines to the European Commission’s “Beating Cancer Plan.” The association has offered a checklist of key policies to “ensure equity and quality of cancer care is achieved.”
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.